Cargando…

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

BACKGROUND: Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular subtypes. MIBCs with neuroendocrine features have a high response rate to immunity checkpoint inhibitors (ICIs). Whether the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manzano, Ramon Gonzalez, Catalan-Latorre, Ana, Brugarolas, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056512/ https://www.ncbi.nlm.nih.gov/pubmed/33879103 http://dx.doi.org/10.1186/s12885-021-08078-y

Ejemplares similares

A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
por: Cai, Ling, et al.
Publicado: (2022)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma
por: Chen, Chung-Hsin, et al.
Publicado: (2016)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
por: Lyu, Qiong, et al.
Publicado: (2020)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Study of polymorphisms in the TP53 and RB1 genes in children with retinoblastoma in northern Mexico
por: Anaya-Pava, Edwin J., et al.
Publicado: (2017)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018)

Correlation of HER2 With p53 and p63 in Urothelial Bladder Carcinoma
por: Ponnaboina, Divya Madhuri, et al.
Publicado: (2023)

NGS Analysis Confirms Common TP53 and RB1 Mutations, and Suggests MYC Amplification in Ocular Adnexal Sebaceous Carcinomas
por: Peterson, Cornelia, et al.
Publicado: (2021)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
por: Li, Junjie, et al.
Publicado: (2021)

TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma
por: Nikolova, Dafina, et al.
Publicado: (2018)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma
por: Dong, Mingwei, et al.
Publicado: (2021)

A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
por: Neuzillet, Yann, et al.
Publicado: (2012)

The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis
por: Liao, Yihao, et al.
Publicado: (2021)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Alsaihati, Burair A., et al.
Publicado: (2021)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Unambiguous Detection of Multiple TP53 Gene Mutations in AAN-Associated Urothelial Cancer in Belgium Using Laser Capture Microdissection
por: Aydin, Selda, et al.
Publicado: (2014)

Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study
por: Soerohardjo, Indrawarman, et al.
Publicado: (2020)

ATM/RB1 mutations predict shorter overall survival in urothelial cancer
por: Yin, Ming, et al.
Publicado: (2018)

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
por: Cao, Jia-Zheng, et al.
Publicado: (2022)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
por: Yang, Y C, et al.
Publicado: (2006)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome
por: Moriya, Kunihiko, et al.
Publicado: (2014)

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2016)

T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts
por: Chen, Y, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dt7eqehgpkf53bgvhahs0s6bq5